Antiviral efficacy of the anesthetic propofol against dengue virus infection and cellular inflammation

Ting Jing Shen; Chia Ling Chen; Ming Kai Jhan; Po Chun Tseng; Rahmat Dani Satria; Chung Hsi Hsing; Chiou Feng Lin

doi:10.1155/2021/6680913

Antiviral efficacy of the anesthetic propofol against dengue virus infection and cellular inflammation

Ting Jing Shen, Chia Ling Chen, Ming Kai Jhan, Po Chun Tseng, Rahmat Dani Satria, Chung Hsi Hsing, Chiou Feng Lin

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Propofol, 2,6-diisopropylphenol, is a short-acting intravenous sedative agent used in adults and children. Current studies show its various antimicrobial as well as anti-inflammatory effects. Dengue virus (DENV) is an emerging infectious pathogen transmitted by mosquitoes that causes mild dengue fever and progressive severe dengue diseases. In the absence of safe vaccines and antiviral agents, adjuvant treatments and supportive care are generally administered. This study investigated the antiviral effects of propofol against DENV infection and cellular inflammation by using an in vitro cell model. Treatment with propofol significantly inhibited DENV release 24 h postinfection in BHK-21 cells. Furthermore, it also blocked viral protein expression independent of the translational blockade. Propofol neither caused inhibitory effects on endosomal acidification nor prevented dsRNA replication. Either the proinflammatory TNF-α or the antiviral STAT1 signaling was reduced by propofol treatment. These results provide evidence to show the potential antiviral effects of the sedative propofol against DENV infection and cellular inflammation.

Original language	English
Article number	6680913
Journal	Journal of Immunology Research
Volume	2021
DOIs	https://doi.org/10.1155/2021/6680913
Publication status	Published - 2021

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1155/2021/6680913

Cite this

@article{1b63144aa20b427d8e323cd3ea167636,

title = "Antiviral efficacy of the anesthetic propofol against dengue virus infection and cellular inflammation",

abstract = "Propofol, 2,6-diisopropylphenol, is a short-acting intravenous sedative agent used in adults and children. Current studies show its various antimicrobial as well as anti-inflammatory effects. Dengue virus (DENV) is an emerging infectious pathogen transmitted by mosquitoes that causes mild dengue fever and progressive severe dengue diseases. In the absence of safe vaccines and antiviral agents, adjuvant treatments and supportive care are generally administered. This study investigated the antiviral effects of propofol against DENV infection and cellular inflammation by using an in vitro cell model. Treatment with propofol significantly inhibited DENV release 24 h postinfection in BHK-21 cells. Furthermore, it also blocked viral protein expression independent of the translational blockade. Propofol neither caused inhibitory effects on endosomal acidification nor prevented dsRNA replication. Either the proinflammatory TNF-α or the antiviral STAT1 signaling was reduced by propofol treatment. These results provide evidence to show the potential antiviral effects of the sedative propofol against DENV infection and cellular inflammation.",

author = "Shen, {Ting Jing} and Chen, {Chia Ling} and Jhan, {Ming Kai} and Tseng, {Po Chun} and Satria, {Rahmat Dani} and Hsing, {Chung Hsi} and Lin, {Chiou Feng}",

note = "Funding Information: This work was supported by grants from the Ministry of Science and Technology (MOST) (108-2320-B-038-026, 109- 2320-B-038-050, 109-2327-B-006-010, and 109-2320-B-038-070), Chi Mei Medical Center, and Taipei Medical University (105CM-TMU-03, 106CM-TMU-09, and 107CM-TMU-10), Taiwan. We thank the Core Facility Center of Taipei Medical University (TMU) for providing technical support. Publisher Copyright: Copyright {\textcopyright} 2021 Ting-Jing Shen et al.",

year = "2021",

doi = "10.1155/2021/6680913",

language = "English",

volume = "2021",

journal = "Journal of Immunology Research",

issn = "2314-8861",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Antiviral efficacy of the anesthetic propofol against dengue virus infection and cellular inflammation

AU - Shen, Ting Jing

AU - Chen, Chia Ling

AU - Jhan, Ming Kai

AU - Tseng, Po Chun

AU - Satria, Rahmat Dani

AU - Hsing, Chung Hsi

AU - Lin, Chiou Feng

N1 - Funding Information: This work was supported by grants from the Ministry of Science and Technology (MOST) (108-2320-B-038-026, 109- 2320-B-038-050, 109-2327-B-006-010, and 109-2320-B-038-070), Chi Mei Medical Center, and Taipei Medical University (105CM-TMU-03, 106CM-TMU-09, and 107CM-TMU-10), Taiwan. We thank the Core Facility Center of Taipei Medical University (TMU) for providing technical support. Publisher Copyright: Copyright © 2021 Ting-Jing Shen et al.

PY - 2021

Y1 - 2021

N2 - Propofol, 2,6-diisopropylphenol, is a short-acting intravenous sedative agent used in adults and children. Current studies show its various antimicrobial as well as anti-inflammatory effects. Dengue virus (DENV) is an emerging infectious pathogen transmitted by mosquitoes that causes mild dengue fever and progressive severe dengue diseases. In the absence of safe vaccines and antiviral agents, adjuvant treatments and supportive care are generally administered. This study investigated the antiviral effects of propofol against DENV infection and cellular inflammation by using an in vitro cell model. Treatment with propofol significantly inhibited DENV release 24 h postinfection in BHK-21 cells. Furthermore, it also blocked viral protein expression independent of the translational blockade. Propofol neither caused inhibitory effects on endosomal acidification nor prevented dsRNA replication. Either the proinflammatory TNF-α or the antiviral STAT1 signaling was reduced by propofol treatment. These results provide evidence to show the potential antiviral effects of the sedative propofol against DENV infection and cellular inflammation.

AB - Propofol, 2,6-diisopropylphenol, is a short-acting intravenous sedative agent used in adults and children. Current studies show its various antimicrobial as well as anti-inflammatory effects. Dengue virus (DENV) is an emerging infectious pathogen transmitted by mosquitoes that causes mild dengue fever and progressive severe dengue diseases. In the absence of safe vaccines and antiviral agents, adjuvant treatments and supportive care are generally administered. This study investigated the antiviral effects of propofol against DENV infection and cellular inflammation by using an in vitro cell model. Treatment with propofol significantly inhibited DENV release 24 h postinfection in BHK-21 cells. Furthermore, it also blocked viral protein expression independent of the translational blockade. Propofol neither caused inhibitory effects on endosomal acidification nor prevented dsRNA replication. Either the proinflammatory TNF-α or the antiviral STAT1 signaling was reduced by propofol treatment. These results provide evidence to show the potential antiviral effects of the sedative propofol against DENV infection and cellular inflammation.

UR - http://www.scopus.com/inward/record.url?scp=85104522395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104522395&partnerID=8YFLogxK

U2 - 10.1155/2021/6680913

DO - 10.1155/2021/6680913

M3 - Article

C2 - 33869639

AN - SCOPUS:85104522395

SN - 2314-8861

VL - 2021

JO - Journal of Immunology Research

JF - Journal of Immunology Research

M1 - 6680913

ER -

Antiviral efficacy of the anesthetic propofol against dengue virus infection and cellular inflammation

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this